Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific's stock has rebounded, increasing by approximately 30% after fears of tariff impacts and R&D cuts. The stock rallied 21.4% in the last month and is up 7.9% year-to-date as of October 28, 2025. In Q3 2025, the company reported strong results, surpassing analysts' expectations with an adjusted EPS of $5.79 and revenue of $11.12 billion, leading to a 2.51% increase in pre-market trading. The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.60 to $22.86. Corporate insiders sold 29,666 shares valued at $13,990,971 in the last three months. Several institutional investors increased their holdings. The company faced headwinds, including declining revenue in the academic and government sectors, and low single-digit growth in diagnostics and healthcare, particularly in China.

Specific detailed patterns for demand seasonality for Thermo Fisher Scientific's products and services are not explicitly provided. The company experienced headwinds in 2023 and 2024 due to declining biopharma venture investment. Revenues increased in Q3 2025, suggesting a recovery. The demand for life sciences and diagnostics is resilient, with the company being a key supplier for biotech, pharma, and research institutions. The ongoing demand for personalized medicine is expected to keep the company thriving.

Thermo Fisher Scientific, Inc. is a global life science and clinical research company providing analytical instruments, clinical development solutions, specialty diagnostics, and laboratory services. The company operates in the laboratory equipment, biotechnology, chemicals, and pharmaceutical industries, aiming to enable customers to make the world healthier, cleaner, and safer. Its offerings are categorized into Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company's portfolio includes brands such as Thermo Scientific, Applied Biosystems, and Invitrogen.

Thermo Fisher Scientific has a significant global presence in North America, Europe, and Asia-Pacific. The United States is its largest market, contributing approximately 48% of total revenues, followed by China. The company is expanding in emerging markets like Southeast Asia, India, and Brazil, establishing Centers of Excellence to enhance its capabilities. Recent expansions include new central laboratory operations in Covington, Kentucky, and a clinical research laboratory building in Middleton, Wisconsin.

Thermo Fisher Scientific has maintained a strong brand reputation through strategic collaborations and product innovation. The company has established partnerships with Moderna, Inc. and Pfizer, and Flagship Pioneering. It received FDA approval for the Oncomine™ Dx Express Test and launched the Olink® Target 48 Neurodegeneration panel and the Thermo Scientific™ Talos™ 12 transmission electron microscope. Thermo Fisher established a strategic collaboration with OpenAI to further integrate artificial intelligence across its operations. The company strengthened its position through acquisitions, including the Filtration and Separation business from Solventum, and Sanofi's Ridgefield, New Jersey, sterile fill-finish site.

Thermo Fisher Scientific's stock ownership is predominantly institutional, with approximately 88.50% held by institutional shareholders, 0.89% by insiders, and 10.62% by retail investors. The Vanguard Group Inc. is the largest individual shareholder, owning approximately 33.79 million shares, representing 8.95% of the company. BlackRock Inc. holds around 27.33 million shares, accounting for 7.24% of the company. State Street Corp. owns approximately 16.48 million shares, representing 4.36% of the company.